Bringing the very best science and medicine to our best equine friends
November 2016

Kindred Biosciences to Present Zimeta Pivotal Data at the 62nd Annual American Association of Equine Practitioners Convention

San Francisco, CA (November 29, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Emily Sundman, DVM, Clinical Development Scientist for KindredBio, will present pivotal effectiveness data for Zimeta™ (dipyrone injection) at the American Association of Equine Practitioners (AAEP) Convention in Orlando, FL on Tuesday, December 6, 2016 at 8:25 AM ET as part of the Internal Medicine track. The presentation will be available at http://kindredbio.com/investor-relations/events/ following the AAEP presentation. Zimeta is a pyrazolone anti-inflammatory drug with a unique mechanism of action that is under development for the …

Continue Reading

Kindred Biosciences to Present at 9th Annual LD Micro Investor Conference

San Francisco, CA (November 18, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Dr. Richard Chin, President and CEO, will be presenting at the 9th Annual LD Micro Investor Conference in Los Angeles, CA on Wednesday, December 7, 2016 at 1:30 PM PT. The conference is being held at the Luxe Sunset Boulevard Hotel. The presentation will be available via a live webcast at the following URL: http://wsw.com/webcast/ldmicro11/kin. An archived version of the webcast and presentation will be available for 30 days on the Company’s website: http://kindredbio.com/investor-relations/events. About …

Continue Reading

Kindred Biosciences Announces Third Quarter 2016 Financial Results

San Francisco, CA (November 7, 2016) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the third quarter ended September 30, 2016 and provided updates on its programs. “We are pleased with the progress across our programs as we execute our strategy of quickly and cost-effectively developing therapeutics for our animal family members. In support of the anticipated launch of Zimeta™ (dipyrone injection) and Mirataz™ (mirtazapine 2% ointment), we have been hiring key personnel, building our veterinary technical services and establishing distribution channels. The advances of our …

Continue Reading